Seek Returns

AMGN vs. INSM: Amgen vs. Insmed Stock Comparison

How do Amgen (AMGN) and Insmed (INSM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Insmed (INSM) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Amgen (AMGN) and Insmed (INSM)
Profile ItemAMGNINSM
NameAmgen Inc. Common StockInsmed Incorporated
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization249.05 billion USD25.10 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 17, 1983June 1, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
INSM
GSPC
Loading price history…
Amgen (AMGN) vs. Insmed (INSM), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Insmed (INSM). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Insmed (INSM). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
Total Return (1Y)48.82%-39.17%
Total Return (3Y, Annualized)24.31%70.17%
Total Return (5Y, Annualized)20.67%28.96%

Risk Profile

Drawdown History

AMGN
INSM
GSPC
Loading price history…
Amgen (AMGN) vs. Insmed (INSM), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Insmed (INSM). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
Volatility (1Y, Annualized)29.12%63.09%
Beta (5Y)0.430.80
Max Drawdown (5Y)-24.86%-56.54%
Avg. Volume (3M)2.76M2.76M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and INSM are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
Sharpe Ratio (1Y)1.53-0.69
Sortino Ratio (1Y)2.36-1.04

Profitability

ROE (TTM)

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Amgen (AMGN) reports 78.35%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-72.45%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
INSM
-72.45%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Amgen (AMGN) reports 24.14%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.85%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
INSM
-39.85%
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Amgen (AMGN) reports 35.79%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-15.60%

Max
83.12%
Q3
14.77%
Median
0.00%
INSM
-15.60%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
ROE (TTM)78.35%-72.45%
ROA (TTM)8.91%-17.25%
Net Margin (TTM)24.14%-39.85%
Operating Margin (TTM)35.79%-15.60%
Gross Margin (TTM)72.47%84.40%

Growth

Revenue Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Amgen (AMGN) at 9.95% is closer to the peer norm — faster top-line expansion for INSM.

Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
Revenue Growth (YoY)9.95%66.73%
Revenue Growth (3Y CAGR)11.77%35.20%
EPS Growth (YoY)88.23%--
EPS Growth (3Y CAGR)5.52%--

Financial Strength

Current Ratio (MRQ)

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

Max
25.13
Q3
12.13
Median
5.52
INSM
2.86
Q1
2.47
Min
0.10
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Insmed (INSM) at 1.01 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max
1.42
INSM
1.01
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
Current Ratio (MRQ)1.482.86
Debt / Equity (MRQ)3.761.01
Net Debt / EBITDA2.31--

Dividends

Dividend Yield (TTM)

Insmed (INSM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Insmed (INSM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
Dividend Yield (TTM)2.16%0.00%
Dividend Payout Ratio (TTM)57.62%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Amgen (AMGN) trades at 26.69 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
INSM
--
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): INSM does not report P/E ratio, so it has no value marker; AMGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Insmed (INSM) at 16.52 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.52

Max
58.18
Q3
25.77
INSM
16.52
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Amgen (AMGN) at 17.35 and Insmed (INSM) at 34.55 look expensive — each P/B ratio sits above its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.55

INSM
34.55
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Amgen (AMGN) vs. Insmed (INSM): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Insmed (INSM)
MetricAMGNINSM
P/E Ratio (TTM)26.69--
P/S Ratio (TTM)6.4016.52
P/B Ratio (MRQ)17.3534.55
Free Cash Flow Yield (TTM)2.96%-1.82%